U.S. markets closed
  • S&P Futures

    3,747.00
    -18.50 (-0.49%)
     
  • Dow Futures

    30,754.00
    -124.00 (-0.40%)
     
  • Nasdaq Futures

    12,373.00
    -82.00 (-0.66%)
     
  • Russell 2000 Futures

    2,122.30
    -22.20 (-1.04%)
     
  • Crude Oil

    64.39
    +0.56 (+0.88%)
     
  • Gold

    1,690.30
    -10.40 (-0.61%)
     
  • Silver

    25.22
    -0.25 (-0.97%)
     
  • EUR/USD

    1.1966
    -0.0013 (-0.11%)
     
  • 10-Yr Bond

    1.5500
    +0.0800 (+5.44%)
     
  • Vix

    28.57
    +1.90 (+7.12%)
     
  • GBP/USD

    1.3896
    +0.0002 (+0.01%)
     
  • USD/JPY

    107.9030
    -0.0730 (-0.07%)
     
  • BTC-USD

    47,029.73
    -4,380.00 (-8.52%)
     
  • CMC Crypto 200

    940.26
    -46.95 (-4.76%)
     
  • FTSE 100

    6,650.88
    -24.59 (-0.37%)
     
  • Nikkei 225

    28,359.11
    -571.00 (-1.97%)
     

AbCellera Announces Date of Fourth Quarter 2020 Financial Results Conference Call

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

AbCellera (Nasdaq: ABCL) will announce its fourth-quarter and full-year 2020 financial results on Monday, March 29, 2021 after the U.S. stock markets close and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.

The live webcast of the earnings conference call can be accessed through a link that will be posted on AbCellera’s Investor Relations website. A replay of the webcast will be available through the same link following the conference call.

About AbCellera Biologics Inc.

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, visit www.abcellera.com.

AbCellera Forward-looking Statements

This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210203005894/en/

Contacts

Inquiries

Media: Jessica Yingling, Ph.D.; media@abcellera.com, +1(236)521-6774
Business Development: Kevin Heyries, Ph.D.; bd@abcellera.com, +1(604)559-9005
Investor Relations: Melanie Solomon; ir@abcellera.com, +1(778)729-9116